LumiraDx Limited (LMDX)
| Market Cap | 203.20M |
| Revenue (ttm) | 254.48M |
| Net Income (ttm) | -449.38M |
| Shares Out | 333.12M |
| EPS (ttm) | -1.59 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 515,210 |
| Open | 0.718 |
| Previous Close | 0.740 |
| Day's Range | 0.590 - 0.763 |
| 52-Week Range | 0.590 - 8.260 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 3.56 (+483.61%) |
| Earnings Date | May 10, 2023 |
About LMDX
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solut... [Read more]
Financial Performance
In 2022, LumiraDx's revenue was $254.48 million, a decrease of -39.62% compared to the previous year's $421.43 million. Losses were -$449.38 million, 345.2% more than in 2021.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for LMDX stock is "Buy." The 12-month stock price forecast is $3.56, which is an increase of 483.61% from the latest price.
News
LumiraDx Limited (LMDX) Reports Q4 Loss, Tops Revenue Estimates
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -68.42% and 7.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
LumiraDx Reports Fourth Quarter and Full Year 2022 Results
LONDON, March 21, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full...
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 f...
LumiraDx to Present at Raymond James Institutional Investors Conference
LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institu...
LumiraDx Regains Compliance with Nasdaq Continued Listing Requirements
LONDON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that it has received confirmation from The Nasdaq Stock Market LLC (“Nasdaq”) that it has rega...
LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced it has commenced commercial shipment of its point of car...
LumiraDx Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
LONDON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it...
LumiraDx Announces New Investment for Ongoing Development of its Point of Care Molecular Tuberculosis Test
Company receives $14.2M in grants from the Bill & Melinda Gates Foundation to support the TB test's ongoing development and future launch into developing countries Company receives $14.2M in grants fr...
Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings
LumiraDx shares these and other findings from its first annual U.K. survey “Point of Care Diagnostics: A Clinicians View” LumiraDx shares these and other findings from its first annual U.K. survey “Po...
Latest Clinicians' U.S. Survey Identifies Point of Care Testing (POCT) as a Way to Address Healthcare Bandwidth Pressures and Anticipates Future Growth of POCT in Community Testing Centers
LumiraDx shares these and other findings from its second annual U.S. survey “Point of Care Diagnostics: A Clinician's View” LumiraDx shares these and other findings from its second annual U.S. survey ...
LumiraDx Continues Commercial Expansion of its Rapid Microfluidic Immunoassay HbA1c Test
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa Early customers include GP offices and other community-based healthcare settings Latest figures, released as part of...
LumiraDx Limited (LMDX) Reports Q3 Loss, Tops Revenue Estimates
LumiraDx Limited (LMDX) delivered earnings and revenue surprises of -56.67% and 46.15%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
LumiraDx Reports Third Quarter 2022 Results
Progress on Near-Term Growth Opportunities and Cost Savings Progress on Near-Term Growth Opportunities and Cost Savings
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on ...
LumiraDx named by Frost & Sullivan as the 2022 Europe Technology Innovation Leader in the Microfluidics Point of Care Diagnostics Industry
The research company recognizes LumiraDx for uniquely leveraging its technology to meet customers' needs and capitalizing on new growth opportunities The research company recognizes LumiraDx for uniqu...
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” Testing Times Re...
LumiraDx Reports Second Quarter 2022 Results
Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products Strong Pipeline Progress and Commercialization Priorities for Newly Authorized Products
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on...
LumiraDx Announces Pricing of Public Offering of Common Shares and Concurrent Private Placement
LONDON , July 21, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced the pricing of its underwritten public offering of 43...
LumiraDx Announces Proposed Public Offering of Common Shares
LONDON , July 19, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced that it has commenced an underwritten public offering...
LumiraDx Achieves CE Mark for COVID-19 Antigen Test on Amira, its New Low-Cost Testing System
Next-generation antigen test system built on more than eight years of research and backed by industry leading microfluidic experts The Amira System includes the Amira Analyzer, Amira SARS-CoV-2 Ag tes...
Why LumiraDx Shares Are Rising Today
LumiraDx Ltd (NASDAQ: LMDX) shares are trading higher by 10.31% at $4.28 after the company announced it achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-...
LumiraDx Receives CE Mark for Two Multiplex Tests: LumiraDx Dual-Target SARS-CoV-2 STAR Complete and LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete
LONDON , June 8, 2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX) today announced that it has achieved CE Mark for two new Fast Lab Solutions molecular tests, including Dual-Target SARS-CoV-2 STAR...
LumiraDx Expands its Cardiovascular Testing Portfolio with CE Marking of its NT-proBNP Test and new Exclusion Claim for its D-Dimer Test
The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are desig...
LumiraDx HbA1c Test Achieves CE Mark, Addresses Growing Global Need for Diabetes Screening and Monitoring with its Next-Generation Point of Care Diagnostic Platform
Rapid microfluidic immunofluorescence assay intended for the monitoring of individuals with diabetes, and as an aid in screening and identifying patients who may be at risk for developing diabetes The...